Cited by 434Adipokines, Inflammation, and Metabolic DiseasesCardiovascular Disease and AdiposityAdipose Tissue and Metabolism

Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease

Matsuzawa, Yuji·2006·Nature Clinical Practice Cardiovascular Medicine

Abstract

Abdominal fat accumulation has been shown to play crucial roles in the development of metabolic syndrome. Visceral fat accumulation particularly is closely correlated to the development of cardiovascular disease and obesity-related disorders such as diabetes mellitus, hyperlipidemia and hypertension. Given these clinical findings, the functions of adipocytes have been intensively investigated in the past 10 years, and have been revealed to act as endocrine cells that secrete various bioactive substances termed adipocytokines. Among adipocytokines, tumor-necrosis factor-alpha, plasminogen activator inhibitor type 1 and heparin-binding epidermal growth factor-like growth factor are produced in adipocytes as well as other organs, and contribute to the development of vascular diseases. Visfatin has been identified as a visceral-fat-specific protein that might be involved in the development of obesity-related diseases, such as diabetes mellitus and cardiovascular disease. In contrast to these adipocytokines, adiponectin, which is an adipose-tissue-specific, collagen-like protein, has been noted as an important antiatherogenic and antidiabetic protein, or as an anti-inflammatory protein. The functions of adipocytokine secretion might be regulated dynamically by nutritional state. Visceral fat accumulation causes dysregulation of adipocyte functions, including oversecretion of tumor-necrosis factor-alpha, plasminogen activator inhibitor type 1 and heparin-binding epidermal growth factor-like growth factor, and hyposecretion of adiponectin, which results in the development of a variety of metabolic and circulatory diseases. In this review, the importance of adipocytokines, particularly adiponectin, is discussed with respect to cardiovascular diseases.

Integrity signals

Registry

Crossref · 10.1038/ncpcardio0380

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Witham et al. provided 100 000 IU vitamin D2 or placebo to elderly patients with systolic heart failure at study entry and after ten weeks and found no effect on plasma TNF-α at ten or twenty weeks.

    “Witham et al. (751) provided 100 000 IU (2500 mg) vitamin D 2 or placebo to elderly patients with systolic heart failure at study entry (week 0) and after 10 weeks and found no effect on plasma TNF-a at 10 or 20 weeks.”

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Matsuzawa, Y.
Venue
Nature Clinical Practice Cardiovascular Medicine
Published
2006-01
Volume
3
Issue
1
Pages
35-42
ISSN
  • 1743-4297 (ISSN-L)
  • 1743-4300
OpenAlex
W2060823593
Cited by
434
References
60
Citations by year
2026: 2 · 2025: 5 · 2024: 3 · 2023: 7 · 2022: 9 · 2021: 7 · 2020: 12 · 2019: 13 · 2018: 9 · 2017: 19 · 2016: 15 · 2015: 24 · 2014: 30 · 2013: 25 · 2012: 33
FWCI
6.75
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Clinical Practice Cardiovascular Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
Keywords
adipokines, metabolic syndrome, cardiovascular disease, adiponectin, TNF-α, plasminogen activator inhibitor-1, HB-EGF, visfatin, visceral fat, obesity, diabetes mellitus, atherosclerosis, anti-inflammatory activity
MeSH terms
Adipose Tissue, Cardiovascular Diseases, Humans, Risk Factors, Cytokines, Metabolic Syndrome, Adiponectin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review